MIRA Pharmaceuticals’ Ketamir-2 Shows Promising Preclinical Results

MIRA Pharmaceuticals, Inc. ( (MIRA) ) just unveiled an announcement.

On August 12, 2025, MIRA Pharmaceuticals announced that its lead drug candidate, Ketamir-2, demonstrated superior efficacy in preclinical models of neuropathic pain compared to ketamine, gabapentin, or pregabalin. The manuscript detailing these findings was accepted for publication in Frontiers in Pharmacology, highlighting Ketamir-2’s potential to restore sensory function and reverse pain behaviors. The global neuropathic pain market is projected to grow significantly, with North America holding a substantial share. MIRA plans to submit a Phase 2a clinical trial protocol to the FDA by Q4 2025, aiming to initiate the study by year-end. Additionally, MIRA is exploring Ketamir-2’s potential in other central nervous system conditions.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative treatments for neuropathic pain and other central nervous system disorders. Its primary product, Ketamir-2, is a lead drug candidate designed to address significant unmet needs in the neuropathic pain market, which is notably underserved in North America.

Average Trading Volume: 1,353,642

Technical Sentiment Signal: Strong Buy

See more data about MIRA stock on TipRanks’ Stock Analysis page.